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Abstract
Background: Attempts to reduce high utilisation of psychiatric inpatient care by targeting the critical time of
hospital discharge have been rare.
Methods: This paper presents design and methods of the study "Effectiveness and Cost-Effectiveness of Needs-
Oriented Discharge Planning and Monitoring for High Utilisers of Psychiatric Services" (NODPAM), a multicentre
RCT conducted in five psychiatric hospitals in Germany. Inclusion criteria are receipt of inpatient psychiatric care,
adult age, diagnosis of schizophrenia or affective disorder, defined high utilisation of psychiatric care during two
years prior to the current admission, and given informed consent. Consecutive recruitment started in April 2006.
Since then, during a period of 18 months, comprehensive outcome data of 490 participants is being collected at
baseline and during three follow-up measurement points.
The manualised intervention applies principles of needs-led care and focuses on the inpatient-outpatient
transition. A trained intervention worker provides two intervention sessions: (a) Discharge planning: Just before
discharge with the patient and responsible clinician at the inpatient service; (b) Monitoring: Three months after
discharge with the patient and outpatient clinician. A written treatment plan is signed by all participants after each
session.
Primary endpoints are whether participants in the intervention group will show fewer hospital days and
readmissions to hospital. Secondary endpoints are better compliance with aftercare, better clinical outcome and
quality of life, as well as cost-effectiveness and cost-utility.
Discussion: If a needs-oriented discharge planning and monitoring proves to be successful in this RCT, a tool
will be at hand to improve patient outcome and reduce costs via harmonising fragmented mental health service
provision.
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Background
Large numbers of psychic patients do not receive aftercare
in the community during the period immediately follow-
ing hospital discharge. The average rate of utilisation of
aftercare is about 50%, with a wide range between 22 and
90% depending on the definition of aftercare [1-3]. More
specifically, one third to one half of patients with schizo-
phrenia and related disorders miss their first scheduled
outpatient appointment after discharge [4]. In addition,
for those who receive follow-up, the delay between dis-
charge and receipt of aftercare (operationalised as first
outpatient visit) has been found to be substantial [1,5].
Thus, limited continuity of service provision is pervasive,
and time lags arising in this process have been found to
increase the probability of relapse and to negatively affect
patients' quality of life [1].
There have been some research efforts aimed at identify-
ing the causes for this failure to utilise psychiatric services
(for an overview see [2]). Results based on patient varia-
bles have been mostly negative, while service system vari-
ables, e.g. availability of discharge planning, have been
found to facilitate access to aftercare. There is some evi-
dence suggesting that patients who receive discharge plan-
ning are more likely to utilise outpatient mental health
services and are less prone to become socially isolated and
require rehospitalisation. Thus, in a sample of N = 104
inpatients with schizophrenia or schizoaffective disorder,
Olfson et al. [6] found that those who had received dis-
charge planning showed significantly better aftercare
compliance (98.1 vs. 62.7%), fewer rehospitalisations
(40% reduction), and better clinical outcome (34.5 vs.
41.0 BPRS-points, ES = .57) at three-month follow-up.
Furthermore, in a sample of 229 inpatients with a primary
psychiatric diagnosis, Boyer et al. [1] found that patients
were significantly more likely to keep their initial outpa-
tient appointment if they were involved in the outpatient
programme before discharge (OR = 2.14 – 3.89) or if the
discharge plan was discussed between inpatient staff and
outpatient clinicians (OR = 3.17).
It appears that rather simple measures – such as timely
face-to-face contact of the inpatient with the follow-up
outpatient therapist(s) and/or smooth transition between
in- and outpatient treatment – are likely to bring about an
increase in successful community tenure. Also a time-lim-
ited critical time intervention [6,7] has been shown to
yield clinical improvement. The impact of extensive strat-
egies such as case management or the introduction of dis-
charge coordinators, on the other hand, has been limited
or controversial.
Nonetheless, the use of bridging strategies in routine prac-
tice is idiosyncratic at best. Boyer et al. [1] showed that
while discussions between in- and outpatient teams
regarding the arrangement of aftercare occur rather fre-
quently (in two thirds of the cases), patient involvement
with outpatient programmes while they are still in hospi-
tal is less common.
Since the 1980s considerable research effort has been
devoted to high utilisation (HU) of psychiatric services.
According to Hadley et al. [8], "the concept of 'heavy use'
typically applies to those persons whose frequency of
admission or duration of inpatient service is substantially
beyond that of the majority of persons receiving similar
treatment" (p. 280). Two extensive literature reviews on
the topic (Kent et al. [9]: 200 publications identified, 72
described; Roick et al. [10]: 250 publications identified,
105 described) showed that overall, 10 – 30% of psychi-
atric patients are identified as high utilisers who consume
between 50 and 80% of service resources.
Probably due to large differences between psychiatric serv-
ice systems, there is no consensus on what constitutes HU.
In operationalising HU, most authors solely relied on an
arbitrary number of readmissions during a given time
period – usually study duration. An analysis of nine stud-
ies pertaining to psychiatric inpatient treatment (cf. table
1 in Kent et al. [9]) showed that a mean number of 3.25
(SD = 1.75) admissions during 2.38 (SD = 1.51) years, i.e.
1.37 admissions per year, was used as the criterion for HU.
This corresponds to Roick et al. [10] who found that over-
all, patients with 1 – 3 inpatient stays during one year are
identified as a high utilisers. This measure is easily acces-
sible, but has also been criticised (e.g. [11]) since patients
with multiple short hospital stays might be wrongly
included (since they do not use excessive resources), and
patients with few very long hospital stays might be
wrongly excluded, especially when observation time is
short. Thus, some authors used cumulated length of stay
Table 1: Study instruments by raters and measurement points.
T0 T1 T2 T3
Research worker CAN-EU CAN-EU CAN-EU CAN-EU
CSSRI-EU CSSRI-EU CSSRI-EU CSSRI-EU
BPRS BPRS BPRS BPRS
HAM-D HAM-D HAM-D HAM-D
MANSA MANSA MANSA MANSA
E Q - 5 DE Q - 5 D E Q - 5 DE Q - 5 D
Clinician GAF GAF
CGI CGI
STAR-C STAR-C
ZUF-THERA
DP satisfaction
Patient SCL-90-R SCL-90-R SCL-90-R SCL-90-R
STAR-P STAR-P STAR-P STAR-P
ZUF-8
DP satisfaction
Notes: DP = Discharge Planning. See text for other abbreviations.BMC Health Services Research 2008, 8:152 http://www.biomedcentral.com/1472-6963/8/152
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(LOS) during a given period (in addition to or instead of
number of readmissions) to identify HU. E.g. Lucas et al.
[12] developed a "heaviness of use" score by combining
the frequency of admissions with the total number of bed
days. Exceptionally, direct treatment costs beyond cumu-
lated inpatient costs including costs for non-inpatient care
(day hospital treatment, outpatient and complementary
care) was applied [13], but data collection is laborious
and might not be worthwhile since costs for inpatient care
make up the largest share (75–92% [9,14]) of total treat-
ment costs.
Objectives and purpose of the study
Objective of the study is to test the following hypotheses.
Primary
High utilisers of psychiatric services who receive a needs-
oriented discharge planning and monitoring programme
will show fewer hospital days and readmissions to hospi-
tal.
Secondary
Subjects receiving the intervention will show better com-
pliance with aftercare as well as better clinical outcome
and quality of life. Furthermore, the intervention will
show cost-effectiveness and cost-utility, and community-
based psychiatrists whose patients receive the new dis-
charge protocol will show better compliance with treat-
ment recommendations.
Methods and design
A clinical trial entitled "Effectiveness and Cost-Effective-
ness of Needs-Oriented Discharge Planning and Monitor-
ing for High Utilisers of Psychiatric Services" (NODPAM)
will be conducted. Coordinating centre (CC) is Ulm Uni-
versity's Department of Psychiatry II (Günzburg). Partici-
pating centres are the Departments of Psychiatry and
Psychotherapy at the Universities of Düsseldorf, Greif-
swald, and Regensburg, and Ulm University's Department
of Psychiatry I (Ravensburg). This paper describes design
and methods of the NODPAM trial as outlined in the trial
protocol which has been submitted to the funding body
(German Research Foundation) on July 15, 2005 after
having attended to the funders' and independent review-
ers' comments on the original proposal and its revision.
Before the start of recruitment in April 2006, minor
changes have been applied1.
Overview
NODPAM is a randomised controlled prospective trial
with four measurement points during an 18-month study
period (see Figure 1, upper part). Assessments will take
place at baseline, three, six, and 18 months after dis-
charge. We believe that this design is appropriate to
answer the research questions since on one hand it allows
to examine the short-term (three months after baseline),
mid-term (six months) and long-term (18 months) effects
of the intervention, and on the other hand, the burden on
participants (patients and clinicians) is not too high
which will help to keep low study attrition. In the event of
rehospitalisation, data assessment will proceed as origi-
nally scheduled, allowing some delay in case the patient
should be in an acute crisis making assessment impossi-
ble. Assessment will be carried out by a research worker
(different in person from the intervention worker).
Randomisation
A central randomisation procedure will be conducted by
an independent unit (Ulm University's Institute for Bio-
metrics). Stratification will be applied since we will con-
duct a multicentre trial, and, furthermore, since the
intervention might have different effects as to diagnostic
criteria, gender, and chronicity. In order to ensure an ade-
quate distribution of patients with regard to these aspects,
strata will be centre (five centres), primary diagnosis
(ICD-10 Chapter V codes F20 – F29 vs. F30 – F39), gender
(male vs. female) and chronicity (shorter vs. equal to or
longer than three years). If during recruitment a patient
fulfils inclusion criteria and has given informed consent,
a fax will be sent to the randomisation centre which will
perform randomisation, generate a patient code, and send
it back to the study centre.
Cluster randomisation (at the clinician level) will not be
employed since it would severely disrupt clinical routine
and might result in undesired between-centre effects. Fur-
thermore, in many wards of the participating services,
only one clinician is present. Moreover, cross-contamina-
tion among inpatient clinicians is not to be expected since
Trial design (timing and projected N for data collection and  intervention) Figure 1
Trial design (timing and projected N for data collection and 
intervention).
490 441 397 357
months
T0 T1 T2 T3
Data collection
Intervention
pre-
discharge 
session
discharge
036 18
post-
discharge 
session
N total
N site 98 88 79 71
N total
N site
245
49
208
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the intervention is low profile, restricted to one pre-dis-
charge session, and will be carried out by a research
worker with limited clinician involvement.
Blinding
Due to the nature of the intervention, patients, clinicians,
and intervention workers cannot be blinded to patient
allocation. The natural flow of the study will also prevent
the research worker from being blinded. Furthermore,
blinding to patient allocation and centre affiliation of
principal and responsible investigators as well as of the
person performing randomisation is considered neither
feasible nor necessary because no related bias is expected,
and a blinded intermediate risk assessment, e.g. in order
to identify excess mortality of participants as could be the
case with invasive interventions or acutely critical condi-
tions, is not required.
Inclusion and exclusion criteria
Inclusion criteria
Psychiatric inpatients between 18–65 years with a primary
diagnosis of schizophrenia, bipolar affective disorder, or
major depression (ICD-10 Chapter V codes F20 – F29 or
F30 – F39). Furthermore, subjects have to be identified as
high utilisers of psychiatric inpatient care. In order to
avoid misclassification, a two-fold criterion consisting of
number of hospitalisations and cumulative LOS prior to
the index admission will be applied; a subject will be
included for participation if he or she, during a 24-month-
period prior to admission: a) has been psychiatrically hos-
pitalised at least twice with a cumulative LOS exceeding
30 days or b) has been psychiatric hospitalised at least
once with a cumulative psychiatric LOS of more than 50
days. This criterion is in accordance with existing evidence
and is also more comprehensive than the one suggested
for psychiatric inpatient care in Germany by Roick et al.
[15] who, regardless of LOS, categorised patients as high
utilisers who, during a 30-month period, had had more
than three admissions.
Exclusion criteria
(a) Primary diagnosis of substance abuse; (b) Presence of
moderate or severe mental handicap (learning disability)
or organic mental disorder; (c) Current treatment by
forensic psychiatric services; (d) Insufficient command of
the German language in order to receive the intervention,
take part in the assessment interviews, and complete
patient questionnaires; (e) Lacking capacity to give valid
consent to participate; (f) Foreseeable inpatient or day
care mental health treatment (including rehabilitation)
extending seven days after discharge from psychiatric
inpatient treatment.
Outcome measures
Assessment will take place at baseline and three (3, 6 and
18 months) follow-up measurement points in each partic-
ipating centre (see Figure 1). Patients will receive a remu-
neration of 30 € for each assessment. Secondary outcomes
will be provided by independent raters (research workers
trained in study instrument use), clinicians, and patients.
See Table 1 for an overview of the instruments used.
Rater perspective (T0 – T3)
Cumulated LOS and number of readmissions during the
study period (primary outcomes) will be assessed by a
research worker at T1 – T3 via the German version of the
"Client Sociodemographic and Service Receipt Inventory"
(CSSRI-EU). This is a standardised instrument for the
comprehensive assessment of mental health service use
and costs [16] of which a German version is available
[17]. It provides detailed information on direct (e.g. hos-
pital in-patient days, out-patient/day care attendances,
community-based service contacts, medication profile)
and indirect (e.g. days of work loss, state benefits, source/
level of income) costs and has been used in a number of
German studies2.
Assessment of needs will be carried out with the German
version of the "Camberwell Assessment of Need – Euro-
pean Version" (CAN-EU [18]), an interviewer-adminis-
tered instrument comprising 22 individual domains of
need. Staff and user ratings can be obtained; we adminis-
tered only the user rating. Psychopathology will be assessed
using the "Brief Psychiatric Rating Scale" (BPRS [19])
which is a standardised instrument for the assessment of
psychopathological symptoms. Depression will be tapped
into using the "Hamilton Depression Scale" (HAM-D
[20]). Quality of life will be measured via a) the "Manches-
ter Short Assessment of Quality of Life" (MANSA [21])
which is a disease specific instrument for the multidimen-
sional assessment of objective and subjective quality of
life in persons with severe mental illness and b) the Euro-
Qol group's EQ-5D, a generic quality of life assessment
instrument which has been developed for the computa-
tion of quality adjusted life years (QALYs) and whose psy-
chometric properties and applicability in persons with
severe mental illness have been tested [22].
Clinician perspective (T0 [inpatient clinician] and T1 [outpatient 
clinician])
Psychosocial functioning will be rated via the "Global
Assessment of Functioning Scale" (GAF [23]) which has
been shown to be a practical and valid instrument in psy-
chiatric research [24]. Overall psychological impairment will
be tapped into via the "Clinical Global Impression Scale"
(CGI [25]). Therapeutic relationship (clinicians' point of
view) will be assessed using a retranslated German versionBMC Health Services Research 2008, 8:152 http://www.biomedcentral.com/1472-6963/8/152
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of the "Scale to assess the therapeutic relationship in com-
munity mental health care" clinician scale (STAR-C [26]).
Satisfaction with therapeutic work in the ambulatory setting
(T1 only) will be covered with a self-developed scale
(ZUF-THERA [27]) consisting of six rephrased items of the
ZUF-8 [28], the German version of the "Client Satisfaction
Questionnaire" (CSQ [29]). The items were rephrased in
that way that outpatient clinicians could give an evalua-
tion of the quality of the given treatment. Satisfaction with
discharge planning (T1 and intervention group only) will
be assessed with a self-developed nine item rating scale.
Patient perspective (T0 – T3)
Psychological impairment will be measured using the Ger-
man version [30] of Derogatis' [31] "Symptom-Check-
List" (SCL-90-R), a widely used and validated self-report
scale. Therapeutic relationship (patients' point of view) will
be assessed using the "Scale to assess the therapeutic rela-
tionship in community mental health care" patient scale
(STAR-P [26]). Satisfaction with outpatient treatment (T1
only) will be covered for the outpatient setting with the
German version (ZUF-8 [28]) of the "Client Satisfaction
Questionnaire" (CSQ [29]). Satisfaction with discharge
planning (T1 and intervention group only) will be assessed
with a self-developed eight item rating scale.
Sample size
Power calculation for a panel study with four points of
assessment was based on the approach suggested by
Hedeker et al. [32]. For a high utiliser population, previ-
ous research [33] found mean number of inpatient days
during 12 months after discharge to be 47 (SD = 83) days
(projected mean number for 18 months = 71 days). Based
on existing studies, the mean reduction of inpatient days
due to the planned intervention was assumed to be 40%.
A small effect size (0.2 SD) should be detected with a
power of 0.80 at a two-tailed significance level of 0.05.
Panel attrition was estimated 10% at each measurement
point. With regard to data analysis, a constant group effect
over time with a random-effect structure and auto-corre-
lated results was expected. A baseline sample size of 242
participants in each group was calculated to be sufficient.
Accordingly, after rounding to no decimals, a total sample
size of 490 participants (N = 98 at each site) will be
included in the study. Participants will be randomly
assigned to the intervention (N = 245, N = 49 per site) or
control group (N = 245, N = 49 per site).
Intervention
For the intervention group, an intervention worker will
provide a coherent package of needs-oriented discharge
planning and monitoring focusing on the care process.
The NODPAM intervention will apply principles of needs-
led care (e.g. [34]) and focus on the inpatient-outpatient
transition, with the intervention worker emphasising con-
tinuity of the care process vis-à-vis both patient and clini-
cians (e.g. [7]). The intervention worker will provide (and
patients will be actively involved in) two manualised
intervention sessions (each of about 45 minutes duration,
see Figure 1, lower part):
Pre-discharge intervention session
The intervention worker obtains the relevant information
of patients' met and unmet needs in a basic plan (results
of the CAN rating) from the research worker. The first
joint (pre-discharge) intervention session in general takes
place seven days prior to hospital discharge with the fol-
lowing people participating: in-patient clinician, patient
and carers if the patient wants to. There is a guided discus-
sion of the critical domains of need identified on the basis
of CAN ratings which require both current and post-dis-
charge measures and/or interventions. The handwritten
draft of the post-discharge treatment plan contains every
addressed need with a precise problem definition, objec-
tives, time-frame regarding goal attainment and persons
responsible for the implementation. The treatment plan is
signed by all participants. A typed version of the pre-dis-
charge treatment plan will be sent to the outpatient clini-
cian and the patient, and the accompanying letter will
include the advice to discuss the plan and monitor its
progress during every contact between them. The inpa-
tient clinician is remunerated with CME credit points for
each NODAPM intervention session and with a book
voucher worth 50 € (once).
Post-discharge intervention session
Three months after discharge, the intervention worker
arranges a second (post-discharge) intervention session
including all stakeholders involved in the outpatient treat-
ment phase: outpatient clinician, patient and relatives if
the patient wants them to be present. Initially, a written
protocol is drafted to summarise critical domains of need
from the first session, their development since discharge,
and the current CAN ratings (at 3-month follow-up). Par-
ticipants are asked if they can name reasons for change
(improvement or deterioration) or stability of ratings in
the related domains.
Subsequently, a revised version of the pre-discharge treat-
ment plan is developed on the basis of current met and
unmet needs and signed by all participants. A typed ver-
sion of the plan will be sent to the outpatient clinician and
the patient with the advice that the plan should be contin-
uously integrated in outpatient treatment, i. e. discussed
and monitored during every contact between the outpa-
tient clinician and patient for a period of at least three
months. The outpatient clinician in private practice isBMC Health Services Research 2008, 8:152 http://www.biomedcentral.com/1472-6963/8/152
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remunerated with CME credit points and 100 € for each
NODPAM intervention session.
Statistical analysis
The primary endpoints will be derived from the difference
in LOS and number of hospitalisations between T0 and
T1, T2, and T3. The secondary endpoints will be calculated
from the differences in sum (or – if applicable – subscale)
scores of the secondary outcome measures between T0
and T1, T2, and T3. Multiple measurement points have
been chosen in order to scrutinise the intervention's effect
over time, especially the question of whether short- and
mid-term effects would persist.
Analyses will start once baseline data have been collected
and cleaned. Descriptives of all outcome measures will be
produced, and outcome trajectories from T0 – T3 will be
examined via exploratory analyses. The effect of the inter-
vention on reduction of number of inpatient days as well
as on clinical outcomes, quality of life, and compliance
will be tested by means of random-effect regression mod-
els including a constant group effect across time [35-37].
Due to the application of a generalised least square (GLS)
estimation weighted for the lengths of the time series for
each case, these models allow the inclusion of cases with
incomplete (unbalanced) data across panels. Due to
expected skewness of the primary dependent variable
(LOS), bootstrapping methods will be applied for the esti-
mation of standard errors and confidence intervals. Cost-
effectiveness of intervention will be tested by means of the
net-benefit approach [38], and its cost-utility by using
QALYs generated from EQ-5D.
Analysis will be carried out according to the principle of
intention-to-treat. In case attrition should exceed the pro-
jected rate of 10%, additional per-protocol analysis will
be performed.
Data monitoring and safety
All trial data will be stored safely at the participating cen-
tres. The CC is responsible for the merging of the data
from the centres and – after data cleaning – redistributing
it to the centres for analysis.
Data Monitoring will be carried out by persons independ-
ent of trial conduct. Before start of data collection, each
participating centre will name a person responsible for
data entry and monitoring to the CC. The following mon-
itoring strategy will be adhered to.
Monitoring of patient recruitment, data collection and application of 
the intervention
Study visits and regular telephone conferences will allow
for a 100% check of essential trial parameters. In particu-
lar, the CC will see to that: (a) All informed consent forms
which have been signed by patients are complete and
safely stored at the participating centres; (b) Every partici-
pating patient meets inclusion criteria; (c) Both the inter-
vention and assessment of outcome criteria, in each
individual patient, are carried out according to the trial
protocol and intervention manual. In addition, before
start of recruitment, trial staff responsible for data collec-
tion and application of the intervention will be trained in
the use of study instruments at the CC, also by external
experts if applicable. As the study progresses, adherence to
instrument and intervention manuals will be continu-
ously monitored and training refreshed if necessary, espe-
cially in case of staff changes.
Monitoring of flow and quality of data
(a) At each centre, data will be entered via identical tem-
plates programmed by CC staff using EpiData  http://
www.epidata.dk/, a reliable software for entering and doc-
umenting data allowing for e.g. the definition of out-of-
range and outlier data as well as logic checks; (b) After
data entry, centres will send copies of data files and com-
pleted questionnaires to the CC which will carry out: (i)
Review: 10% of the data will be entered again by the CC
and subsequently compared with the data in the files
received from the participating centres. In case of major
differences, proportion of the reviewed data will be
increased; (ii) Query: In case of mismatch, the CC will
contact the respective participating centre in order to cor-
rect data problems. Results of these queries will be com-
municated to the group.
Furthermore, a trial steering committee (TSC) was estab-
lished in its function as an independent board of mem-
bers to provide overall supervision and protection for the
trial participants and the principal investigators. In view
of the non-invasive intervention, the risk for participating
patients is considered marginal. Should, for any unfore-
seeable reason, the intervention or data collection place a
burden on a given participant and should at the same time
he or she be unwilling to terminate participation, the
research worker and/or intervention worker are required
to report this to the TSC who will then decide on whether
or not the participant will have to be excluded. Such
instances will be documented thoroughly.
The advisory board, the TSC and Ulm University Hospital
will be continuously informed of study progress including
data quality issues.
Ethics
Patient confidentiality will be strictly maintained, i.e. by
no means will publications contain person-related infor-
mation. However, the conduct of a longitudinal trial
requires patient follow-up. Thus, study participants' per-
sonal data (e.g. names and addresses) will be recorded forBMC Health Services Research 2008, 8:152 http://www.biomedcentral.com/1472-6963/8/152
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the duration of the trial. Patient ID data will be stored
safely and kept separate from the data set used for analy-
ses.
In the course of recruitment, the research worker will
devote special attention to providing the patients with
detailed information on the trial so they have a sound
basis on which to decide on informed consent. It will be
made clear to the patient that he or she can withdraw con-
sent at any time during the course of the study without
any consequences. In case the patient is under legal cus-
tody, the custodian's consent does not suffice. All partici-
pating centres' ethics committees will have issued positive
votes on NODPAM before the start of the study.
Discussion
There is broad consensus that relapse prevention is one of
the major aims of aftercare. However, the success of
attempts to reduce high re-hospitalisation rates in people
suffering from severe mental disorders has been limited so
far. Insufficient discharge planning and follow-up is con-
sidered one of the main reasons for limited community
tenure and unfavourable clinical outcomes. Only a small
number of RCTs have been conducted to test this assump-
tion.
Literature reviews conclude that specific interventions tar-
geting the needs of high utilisers and subsequently pre-
venting unnecessary high service use should be developed
and evaluated as to their use for patients and clinicians
[9,10,39].
Furthermore, taking into account the finding that health
service costs make up 76% of the total costs, and that 59%
of these are inpatient costs [14], any intervention that is
effective in reducing the heavy inpatient bed use of heavy
users should have a substantial effect on the total service
costs [12,38]. Since service use patterns of high utilisers
appear to depend on service system rather than on indi-
vidual patient variables [8], it has been specifically recom-
mended to identify gaps in current service provision [9],
and – as outlined above – discharge from psychiatric hos-
pital obviously can be considered such a gap, particularly
in fragmented service systems such as the German one.
If this needs-oriented discharge planning and monitoring
intervention proves to be successful in this RCT, a tool will
be at hand (a) to harmonise fragmented service provision,
i.e. improve collaboration of in- and outpatient services
and continuity of care; (b) to improve community tenure,
clinical impairment, and quality of life; and (c) to reduce
unnecessary inpatient treatment costs.
Footnotes
1 These were: (a) Randomisation strata: Originally
planned strata were centre, primary diagnosis, and GAF
score at admission. GAF score at admission was replaced
by gender and illness duration. (b) Original exclusion cri-
terion was only that subjects with a primary diagnosis of
substance abuse will be excluded. (c) Originally the Help-
ing Alliance Questionnaire (HAQ) was intended to be
used for the assessment of the quality of the therapeutic
relationship (changed to STAR); (e) Application of instru-
ments to assess treatment satisfaction (ZUF-8 and ZUF-
THERA) and satisfaction with discharge planning; (d)
Specification of details on amount and kind of clinician
remuneration.
2 The CSSRI-EU also serves to assess necessary informa-
tion pertaining to SES (work, financial and living situa-
tion) and service utilisation beyond inpatient care.
Furthermore, basic patient data will be available via the
"BADO" which has been implemented at all participating
centres.
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